[Osteocalcin and hyperthyroidism].
Osteoporosis may be induced by hyperthyroidism through an increase of bone turnover, because bone resorption exceeds formation in this condition. Also therapy with 1-thyroxine, especially by TSH-suppressive doses, may induce a reduction in bone mineral content. Circulating osteocalcin (sBGP) significantly increases both in endogenous and exogenous hyperthyroxinemia and is considered a reliable non invasive marker of bone turnover. In this study an extra-increase of sBGP in hyperthyroid post-menopausal women towards pre-menopausal is reported, the persistence of high sBGP levels in patients affected by any type of hyperthyroidism after four months of therapy and a positive relationship with thyroid hormones (fT4). Therefore monitoring of this serum marker may be suggested also in patient chronically treated with 1-thyroxine to avoid, if possible, overzealous therapy.
Pandolfi
C
C
I Divisione Medica, Ospedale Maggiore, Lodi, Milano.
Montanari
G
G
Mercantini
F
F
Sbalzarini
G
G
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*
D015415:Biomarkers; D015675:Osteocalcin
Osteocalcina e ipertiroidismo.